Controlled expansion of human endothelial cell populations by Cre-loxP-based reversible immortalization

Hirofumi Noguchi, Tadayoshi Ueda, Masahiro Miyazaki, Masakiyo Sakaguchi, Philippe Leboulch, Naoya Kobayashi, Karen A. Westerman, Masakiyo Sakaguchi, Toshiyoshi Fujiwara, Toshinori Totsugawa, Takamasa Watanabe, Toshihisa Matsumura, Toshiyoshi Fujiwara

Research output: Contribution to journalArticle

38 Citations (Scopus)

Abstract

Endothelial cells (ECs) play multiple physiological functions and are central to many pathological processes. Various biological studies as well as cell and gene therapy applications would benefit substantially from a procedure that would result in the expansion in culture of large numbers of highly differentiated human ECs. Here, we report the amplification in vitro of human EC populations, which occurred during the first phase of reversible immortalization resulting from the retroviral transfer of an oncogene that was subsequently excised by Cre-loxP-mediated site-specific recombination. Human umbilical vein endothelial cells (HUVECs) and human liver sinusoidal endothelial cells (HLSECs) were transduced with a retroviral vector that expresses the simian virus 40 large T (SV40T) gene flanked by positive and negative selectable markers and a pair of loxP recombination targets. Transduced HUVECs and HLSECs yielded clones with greatly extended life spans, referred to as HNNT-1 and HNNT-2 cells, respectively. HNNT-1 and HNNT-2 cells showed morphological characteristics of ECs and were maintained in culture up to population doubling level (PDL) 80 for HNNT-1 and PDL 65 for HNNT-2 cells. HNNT-1 and HNNT-2 cells were not tumorigenic when transplanted into severe combined immunodeficiency mice and were sensitive to ganciclovir as well as G418. Both cell clones expressed EC markers, which include factor VIII, VEGF receptors (Flt-1 and KDR/Flk-1), and CD34, and endocytosed acetylated low-density lipoproteins. Formation of capillary-like structures in a Matrigel assay was observed with HNNT-1 and HNNT-2 cells until at least PDL 50. Complete elimination of the transferred SV40T gene was achieved in virtually 100% of HNNT-1 and HNNT-2 cells after infection with a recombinant adenovirus expressing the Cre recombinase fused to a nuclear localization signal and subsequent selection with G418. Reverted cells maintained their differentiated EC phenotype. This study extends the utility of the reversible immortalization procedure and provides a means to expand primary human ECs of various sources for basic studies and possible cell and gene therapies.

Original languageEnglish
Pages (from-to)321-334
Number of pages14
JournalHuman Gene Therapy
Volume13
Issue number2
DOIs
Publication statusPublished - 2002

Fingerprint

Endothelial Cells
Population
Simian virus 40
Human Umbilical Vein Endothelial Cells
Cell- and Tissue-Based Therapy
Genetic Therapy
Genetic Recombination
Clone Cells
Severe Combined Immunodeficiency
Nuclear Localization Signals
Vascular Endothelial Growth Factor Receptor
Ganciclovir
Liver
Pathologic Processes
Endocytosis
Oncogenes
Adenoviridae
Genes
Phenotype
Infection

ASJC Scopus subject areas

  • Genetics

Cite this

Controlled expansion of human endothelial cell populations by Cre-loxP-based reversible immortalization. / Noguchi, Hirofumi; Ueda, Tadayoshi; Miyazaki, Masahiro; Sakaguchi, Masakiyo; Leboulch, Philippe; Kobayashi, Naoya; Westerman, Karen A.; Sakaguchi, Masakiyo; Fujiwara, Toshiyoshi; Totsugawa, Toshinori; Watanabe, Takamasa; Matsumura, Toshihisa; Fujiwara, Toshiyoshi.

In: Human Gene Therapy, Vol. 13, No. 2, 2002, p. 321-334.

Research output: Contribution to journalArticle

Noguchi, H, Ueda, T, Miyazaki, M, Sakaguchi, M, Leboulch, P, Kobayashi, N, Westerman, KA, Sakaguchi, M, Fujiwara, T, Totsugawa, T, Watanabe, T, Matsumura, T & Fujiwara, T 2002, 'Controlled expansion of human endothelial cell populations by Cre-loxP-based reversible immortalization', Human Gene Therapy, vol. 13, no. 2, pp. 321-334. https://doi.org/10.1089/10430340252769833
Noguchi, Hirofumi ; Ueda, Tadayoshi ; Miyazaki, Masahiro ; Sakaguchi, Masakiyo ; Leboulch, Philippe ; Kobayashi, Naoya ; Westerman, Karen A. ; Sakaguchi, Masakiyo ; Fujiwara, Toshiyoshi ; Totsugawa, Toshinori ; Watanabe, Takamasa ; Matsumura, Toshihisa ; Fujiwara, Toshiyoshi. / Controlled expansion of human endothelial cell populations by Cre-loxP-based reversible immortalization. In: Human Gene Therapy. 2002 ; Vol. 13, No. 2. pp. 321-334.
@article{eb665300b4be48c99cd7f94a5b4746a9,
title = "Controlled expansion of human endothelial cell populations by Cre-loxP-based reversible immortalization",
abstract = "Endothelial cells (ECs) play multiple physiological functions and are central to many pathological processes. Various biological studies as well as cell and gene therapy applications would benefit substantially from a procedure that would result in the expansion in culture of large numbers of highly differentiated human ECs. Here, we report the amplification in vitro of human EC populations, which occurred during the first phase of reversible immortalization resulting from the retroviral transfer of an oncogene that was subsequently excised by Cre-loxP-mediated site-specific recombination. Human umbilical vein endothelial cells (HUVECs) and human liver sinusoidal endothelial cells (HLSECs) were transduced with a retroviral vector that expresses the simian virus 40 large T (SV40T) gene flanked by positive and negative selectable markers and a pair of loxP recombination targets. Transduced HUVECs and HLSECs yielded clones with greatly extended life spans, referred to as HNNT-1 and HNNT-2 cells, respectively. HNNT-1 and HNNT-2 cells showed morphological characteristics of ECs and were maintained in culture up to population doubling level (PDL) 80 for HNNT-1 and PDL 65 for HNNT-2 cells. HNNT-1 and HNNT-2 cells were not tumorigenic when transplanted into severe combined immunodeficiency mice and were sensitive to ganciclovir as well as G418. Both cell clones expressed EC markers, which include factor VIII, VEGF receptors (Flt-1 and KDR/Flk-1), and CD34, and endocytosed acetylated low-density lipoproteins. Formation of capillary-like structures in a Matrigel assay was observed with HNNT-1 and HNNT-2 cells until at least PDL 50. Complete elimination of the transferred SV40T gene was achieved in virtually 100{\%} of HNNT-1 and HNNT-2 cells after infection with a recombinant adenovirus expressing the Cre recombinase fused to a nuclear localization signal and subsequent selection with G418. Reverted cells maintained their differentiated EC phenotype. This study extends the utility of the reversible immortalization procedure and provides a means to expand primary human ECs of various sources for basic studies and possible cell and gene therapies.",
author = "Hirofumi Noguchi and Tadayoshi Ueda and Masahiro Miyazaki and Masakiyo Sakaguchi and Philippe Leboulch and Naoya Kobayashi and Westerman, {Karen A.} and Masakiyo Sakaguchi and Toshiyoshi Fujiwara and Toshinori Totsugawa and Takamasa Watanabe and Toshihisa Matsumura and Toshiyoshi Fujiwara",
year = "2002",
doi = "10.1089/10430340252769833",
language = "English",
volume = "13",
pages = "321--334",
journal = "Human Gene Therapy",
issn = "1043-0342",
publisher = "Mary Ann Liebert Inc.",
number = "2",

}

TY - JOUR

T1 - Controlled expansion of human endothelial cell populations by Cre-loxP-based reversible immortalization

AU - Noguchi, Hirofumi

AU - Ueda, Tadayoshi

AU - Miyazaki, Masahiro

AU - Sakaguchi, Masakiyo

AU - Leboulch, Philippe

AU - Kobayashi, Naoya

AU - Westerman, Karen A.

AU - Sakaguchi, Masakiyo

AU - Fujiwara, Toshiyoshi

AU - Totsugawa, Toshinori

AU - Watanabe, Takamasa

AU - Matsumura, Toshihisa

AU - Fujiwara, Toshiyoshi

PY - 2002

Y1 - 2002

N2 - Endothelial cells (ECs) play multiple physiological functions and are central to many pathological processes. Various biological studies as well as cell and gene therapy applications would benefit substantially from a procedure that would result in the expansion in culture of large numbers of highly differentiated human ECs. Here, we report the amplification in vitro of human EC populations, which occurred during the first phase of reversible immortalization resulting from the retroviral transfer of an oncogene that was subsequently excised by Cre-loxP-mediated site-specific recombination. Human umbilical vein endothelial cells (HUVECs) and human liver sinusoidal endothelial cells (HLSECs) were transduced with a retroviral vector that expresses the simian virus 40 large T (SV40T) gene flanked by positive and negative selectable markers and a pair of loxP recombination targets. Transduced HUVECs and HLSECs yielded clones with greatly extended life spans, referred to as HNNT-1 and HNNT-2 cells, respectively. HNNT-1 and HNNT-2 cells showed morphological characteristics of ECs and were maintained in culture up to population doubling level (PDL) 80 for HNNT-1 and PDL 65 for HNNT-2 cells. HNNT-1 and HNNT-2 cells were not tumorigenic when transplanted into severe combined immunodeficiency mice and were sensitive to ganciclovir as well as G418. Both cell clones expressed EC markers, which include factor VIII, VEGF receptors (Flt-1 and KDR/Flk-1), and CD34, and endocytosed acetylated low-density lipoproteins. Formation of capillary-like structures in a Matrigel assay was observed with HNNT-1 and HNNT-2 cells until at least PDL 50. Complete elimination of the transferred SV40T gene was achieved in virtually 100% of HNNT-1 and HNNT-2 cells after infection with a recombinant adenovirus expressing the Cre recombinase fused to a nuclear localization signal and subsequent selection with G418. Reverted cells maintained their differentiated EC phenotype. This study extends the utility of the reversible immortalization procedure and provides a means to expand primary human ECs of various sources for basic studies and possible cell and gene therapies.

AB - Endothelial cells (ECs) play multiple physiological functions and are central to many pathological processes. Various biological studies as well as cell and gene therapy applications would benefit substantially from a procedure that would result in the expansion in culture of large numbers of highly differentiated human ECs. Here, we report the amplification in vitro of human EC populations, which occurred during the first phase of reversible immortalization resulting from the retroviral transfer of an oncogene that was subsequently excised by Cre-loxP-mediated site-specific recombination. Human umbilical vein endothelial cells (HUVECs) and human liver sinusoidal endothelial cells (HLSECs) were transduced with a retroviral vector that expresses the simian virus 40 large T (SV40T) gene flanked by positive and negative selectable markers and a pair of loxP recombination targets. Transduced HUVECs and HLSECs yielded clones with greatly extended life spans, referred to as HNNT-1 and HNNT-2 cells, respectively. HNNT-1 and HNNT-2 cells showed morphological characteristics of ECs and were maintained in culture up to population doubling level (PDL) 80 for HNNT-1 and PDL 65 for HNNT-2 cells. HNNT-1 and HNNT-2 cells were not tumorigenic when transplanted into severe combined immunodeficiency mice and were sensitive to ganciclovir as well as G418. Both cell clones expressed EC markers, which include factor VIII, VEGF receptors (Flt-1 and KDR/Flk-1), and CD34, and endocytosed acetylated low-density lipoproteins. Formation of capillary-like structures in a Matrigel assay was observed with HNNT-1 and HNNT-2 cells until at least PDL 50. Complete elimination of the transferred SV40T gene was achieved in virtually 100% of HNNT-1 and HNNT-2 cells after infection with a recombinant adenovirus expressing the Cre recombinase fused to a nuclear localization signal and subsequent selection with G418. Reverted cells maintained their differentiated EC phenotype. This study extends the utility of the reversible immortalization procedure and provides a means to expand primary human ECs of various sources for basic studies and possible cell and gene therapies.

UR - http://www.scopus.com/inward/record.url?scp=0036169050&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036169050&partnerID=8YFLogxK

U2 - 10.1089/10430340252769833

DO - 10.1089/10430340252769833

M3 - Article

VL - 13

SP - 321

EP - 334

JO - Human Gene Therapy

JF - Human Gene Therapy

SN - 1043-0342

IS - 2

ER -